Next-generation enzymatic theraputics focused on for non-surgical tissue repair
The company’s unique platform is a mixture of proteolytic enzymes enriched in bromelain. These enzymes are extracted from the pineapple stem, purified and enriched utilizing our proprietary enzymes enrichment technology.
This core technology is the common denominator underlying our marketed product and all our biologic products under development. Bromelain has multiple methods of action that apply to a variety of indications. Our goal is to pioneer non-surgical solutions that can replace existing standards of care, with a current focus in therapeutics for tissue repair.
MediWound’s enzyme enrichment technology harnesses nature’s wisdom while maximizing its biotherapeutic properties for medical therapies.
The process is characterized by the ability to enrich the natural substance with its most active components while maintaining their highest activity during all process stages, from plant harvesting through the pharmaceutical product on the shelf.
From Plant to Drug
Our pharmaceutical product ingredient (API) is a complex mixture of proteins, enriched in bromelain, extracted from the stem of the pineapple. The API possess various pharmacological properties, including:
NexoBrid® is currently marketed in the United States, European Union, Japan, India, and other international markets. Its development is supported by the US Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS).
EscharEx®, based on the same active pharmaceutical ingredient as NexoBrid and indicated for the debridement of chronic and hard-to-heal wounds, is MediWound’s lead biologic under development. Results from Phase 2 studies show that EscharEx is significantly more effective and faster than SOC or placebo control in debridement of VLUs and DFUs, with a good safety and tolerability profile. The Phase 3 study is expected to start in Q4 2023.
MW005, our topical biological drug under development for the treatment of low-risk Basal Cell Carcinoma (BCC). In a Phase I/II open-label, multicenter, randomized clinical trial conducted in the U.S., MW005 was shown to be safe, well-tolerated, and an effective treatment for BCC with patients demonstrating complete clinical and histological clearance of target lesions. The trial is ongoing to optimize formulation and application, with results expected in Q3 2023.